Empery Asset Management LP Sells 123,000 Shares of Satellos Bioscience Inc. $MSLE

Empery Asset Management LP trimmed its holdings in Satellos Bioscience Inc. (NASDAQ:MSLE) by 53.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 107,100 shares of the company’s stock after selling 123,000 shares during the quarter. Satellos Bioscience makes up approximately 0.0% of Empery Asset Management LP’s holdings, making the stock its 15th biggest position. Empery Asset Management LP owned 0.51% of Satellos Bioscience worth $832,703 as of its most recent SEC filing.

Satellos Bioscience Trading Down 5.9%

Shares of MSLE traded down $0.57 during midday trading on Friday, hitting $9.04. 11,297 shares of the stock were exchanged, compared to its average volume of 57,247. The firm has a market cap of $191.83 million, a price-to-earnings ratio of -4.71 and a beta of 1.51. Satellos Bioscience Inc. has a 52-week low of $5.22 and a 52-week high of $13.39. The stock’s fifty day moving average is $8.91.

Satellos Bioscience (NASDAQ:MSLE) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.18). As a group, equities research analysts anticipate that Satellos Bioscience Inc. will post -2.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on MSLE shares. Canaccord Genuity Group upgraded Satellos Bioscience to a “moderate buy” rating in a report on Thursday, May 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. Wells Fargo & Company set a $18.00 target price on Satellos Bioscience in a research report on Thursday, July 9th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Satellos Bioscience in a research report on Monday, August 17th. Finally, Wall Street Zen raised shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.75.

Satellos Bioscience Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.